U.S. markets close in 2 hours 8 minutes

Clover Health Investments, Corp. (CLOV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.51-1.16 (-12.00%)
As of 1:52PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close9.67
Open9.41
Bid8.51 x 2200
Ask8.52 x 3200
Day's Range8.36 - 9.42
52 Week Range6.31 - 17.45
Volume34,710,897
Avg. Volume23,750,082
Market Cap3.458B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Update: Chamath-Backed Clover Health in Apparent Squeeze with Massive Short Interest Reminiscent of GameStop
      IPO-Edge.com

      Update: Chamath-Backed Clover Health in Apparent Squeeze with Massive Short Interest Reminiscent of GameStop

      Chamath Palihapitiya By Jarrett Banks and John Jannarone Short interest in Chamath Palihapitiya-backed Clover Health Investments Corp. (Nasdaq: CLOV) is at 40.6 million shares, data compiled by financial analytics firm S3 Partners shows. This reflects approximately 37% of the float according to an updated estimate from FactSet, which changed over the weekend after IPO Edge covered the […]

    • Demetrios Kouzoukas, Former Director of the Center for Medicare and Principal Deputy Administrator of CMS, Joins Board of Clover Health
      GlobeNewswire

      Demetrios Kouzoukas, Former Director of the Center for Medicare and Principal Deputy Administrator of CMS, Joins Board of Clover Health

      NASHVILLE, Tenn., April 15, 2021 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover”), an innovative technology company improving health outcomes for America's seniors, today announced Demetrios L. Kouzakas has joined its Board of Directors and will serve as a member of the Audit Committee. “Clover and the U.S. government have a shared mission of supporting the health of Medicare beneficiaries and making every tax dollar as impactful as possible,” said Chief Executive Officer Vivek Garipalli. “Demetrios is a significant addition to the Board. Having led the legal and regulatory affairs department of the Medicare division at UnitedHealth, he understands the opportunity and challenge of operating at scale. He has an encyclopedic knowledge of Medicare rules and regulations, combined with an incredibly astute business and strategy acumen. We are grateful that Demetrios is joining us on this very important journey.” For the last four years, until January 2021, Demetrios L. Kouzoukas served as the Director of the Center for Medicare and the Principal Deputy Administrator of the Centers for Medicare & Medicaid Services (CMS). In those roles, he oversaw all operations and policy development for the Medicare Fee-for-Service Program, and the Medicare Advantage and Medicare Prescription Drug Programs. Prior to joining CMS, from 2012 to 2016, Demetrios served as General Counsel of UnitedHealthcare’s Medicare & Retirement division, and prior to that, from 2003 to 2009, he served in the U.S. Department of Health and Human Services (HHS), where he was Principal Associate Deputy Secretary, with responsibility for regulatory policy across HHS, and Deputy General Counsel. Demetrios has also advised a broad spectrum of entities in the healthcare system, focusing on evolving regulatory frameworks and new business models. Demetrios’ expertise in administrative law, government procedure, and public administration was recognized by the Administrative Conference of the United States, which appointed him a Public Member in 2014. "I’m excited to join the Board because Clover empowers the physician with its technology, leading to better care coordination and patient communications. Clover has built its pioneering business around real-time doctor patient interaction -- and that opens the door to solving the hardest challenges in healthcare. Clover’s technology is designed to allow physicians to instantly address patient needs in an individualized manner by providing vital health plan resources and benefits beyond what is typically immediately available to the particular physician or health system. I believe the sum effect of this will be better care, lower costs and greater access," said Kouzoukas. About Clover HealthClover Health (Nasdaq: CLOV) is a healthcare technology company with a deeply rooted mission of improving every life. Clover uses its proprietary technology platform to collect, structure, and analyze health and behavioral data to improve medical outcomes and lower costs for patients. As a company whose business goals align with its members' health needs, Clover works with members and their doctors to become a valued partner. This trust is built by proactively identifying at-risk individuals and teaming up with physicians to accelerate care coordination and simultaneously improve health outcomes and reduce avoidable costs. Clover has offices in Nashville, San Francisco, Jersey City and Hong Kong. Press Contact:Andrew Still-Baxterpress@cloverhealth.com

    • Clover appoints Trump official, industry vet to board amid market struggles, Medicare push
      Yahoo Finance

      Clover appoints Trump official, industry vet to board amid market struggles, Medicare push

      Clover appoints new board member, former CMS official, to help grow company.